According to the diagnostic guidelines of the International Working Group and the US National Institute on Aging Alzheimer’s Association (NIA-AA), AD status is associated with β-amyloid (Aβ) pathology, tau pathology, other biomarkers of neurodegeneration such as fluorodeoxyglucose positron emission tomography (Dubois et al., 2014; Jack et al., 2018). Here, MAPT is linked to Alzheimer disease.